References,Sample size,Interventions,Main race,Female (%),Mean HAMA,Mean age (Year),Attrition rate (%),Sponsor,Follow-up time (weeks),Diagnosis criteria
"Bandelow et al., 2010",873,placebo,White,62.2,27.3,41.2,18.9,AstraZeneca Pharmaceuticals,10,dsm-iv
"Bandelow et al., 2010",873,quetiapine xr: 50 mg/day,White,68.0,26.9,40.7,25.8,AstraZeneca Pharmaceuticals,10,dsm-iv
"Bandelow et al., 2010",873,quetiapine xr: 150 mg/day,White,66.7,26.6,42.3,25.2,AstraZeneca Pharmaceuticals,10,dsm-iv
"Bandelow et al., 2010",873,paroxetine: 20 mg/day,White,64.5,27.1,41.6,20.3,AstraZeneca Pharmaceuticals,10,dsm-iv
